Swiss drugmaker Novartis to invest $23bn in US manufacturing and R&D
- Novartis will invest $23 billion in the United States to build seven new facilities and expand others over the next five years.
- This investment aims to create nearly 1,000 jobs at Novartis and approximately 4,000 additional jobs in the U.S.
- Two new manufacturing plants will be located in Florida and Texas, with expansions in Indiana, New Jersey, and California.
27 Articles
27 Articles
Swiss pharmaceutical giant Novartis to open $1.1 billion global research hub in San Diego
The Novartis logo is seen on a new cell and gene therapy factory in Stein, Switzerland. (File photo by Arnd Wiegmann/Reuters) Swiss pharmaceutical giant Novartis announced it will spend $23 billion to build and expand 10 facilities in the United States, including a research hub in San Diego, as it grapples with renewed threats of drug tariffs from the Trump administration. Novartis said it plans to build six new manufacturing plants, some of whi…
Swiss pharmaceutical giant announces plans for $1.1B campus in San Diego
SAN DIEGO (FOX 5/KUSI) — Swiss pharmaceutical company, Novartis, has announced plans to build a new, $1.1 billion biomedical research complex in San Diego as part of a wider effort to expand its operations in the U.S. over the next five years. The new facility will be the company's second research and development hub in the U.S. and, according to a release announcing the move Thursday, is expected to serve as the "epicenter" of its work in biome…

Pharma Company Announces Big Investment Into United States
The Swiss Pharmaceutical company Novartis is planning on building seven facilities and expanding investment in the United States amid Donald Trump’s tariff announcements. Six of the facilities will be manufacturing plants. Breitbart reported: Pharmaceutical company Novartis announced plans to build seven facilities in the United States and expand others in a $23 billion investment over five years on the heels of President Donald Trump’s announce…
Coverage Details
Bias Distribution
- 50% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage